| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Given Douglas B serves as a Director at ARWR. Across recent SEC filings that breaks down to 1 buy and 21 sells. Those positions are worth an estimated $11.1M at current prices.
Historically, Given Douglas B's trades have earned a middling insider score of 66/100 across 9 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +0.8%.
The biggest single holding is ARWR (~$11.1M) as Director. The recent filings there lean toward selling, a net 181,378 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 17, 2020 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 9,575 | $79.32 | $759,442.50 | -6.9% | |
| Apr 14, 2020 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 25,000 | $36.89 | $922,250.00 | -13.8% | |
| Feb 26, 2019 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sale+OE | 68,000 | $19.20 | $1,305,400.00 | -16.3% | |
| Jan 22, 2019 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 3,000 | $13.58 | $40,740.00 | -1.7% | |
| Dec 27, 2018 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 3,000 | $12.00 | $36,000.00 | -2.0% | |
| Nov 23, 2018 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 3,000 | $12.74 | $38,220.00 | -2.0% | |
| Apr 24, 2018 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 25,000 | $6.63 | $165,750.00 | -13.9% | |
| Oct 14, 2016 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 12,000 | $6.72 | $80,640.00 | -14.6% |